… ProQR update and additional sepofarsen Illuminate trial … and restructuring initiatives: Focus the ultevursen (QR-421a) program for USH2A -mediated Usher syndrome and … with regulatory authorities. Suspend development of QR-1123 for autosomal dominant retinitis pigmentosa and QR-504a …
The EFF is a growing multiple stakeholder platform for the exchange and sharing of insights and innovations to drive the future of clinical development in inherited retinal diseases. Organized by ProQR
… sepofarsen for CEP290 -mediated LCA10 on track for H1 2022 QR-421a pivotal Sirius and Celeste Phase 2/3 trials in Usher … Initial clinical data from Phase 1/2 Aurora trial of QR-1123 for autosomal dominant retinitis pigmentosa expected in …
… data reported from the Phase 1/2 clinical trial of QR-421a for the treatment of Usher syndrome and non-syndromic … We are on track to share the first clinical data for QR-1123 for adRP in the second half of the year, as well as an …
… Phase 2/3 Sirius and Celeste clinical trials of ultevursen (QR-421a) in Usher syndrome and retinitis pigmentosa underway; … by year-end 2022 Repeated dose study planned for QR-1123 for autosomal dominant retinitis pigmentosa and initial …
… trial getting underway and expected to enroll 10 patients. QR-421a for USH2A -mediated Usher syndrome and retinitis … to share an update from the Helia study by year end 2022. QR-1123 for RHO -mediated autosomal dominant retinitis …
… upfront and equity and up to $1.25 billion in milestones QR-421a Phase 2/3 Sirius and Celeste trials in Usher syndrome … end of the year. In Q4 we will share an update from our QR-1123 program in adRP and our QR-504a Fuchs Focus trial is …
… in LCA10 patients, initiating the first-in-human trial for QR-421a for usher syndrome type 2 and advancing QR-1123 further towards the clinic,” said Daniel A. de Boer, CEO … Highlights and Business Update Sepofarsen (formerly QR-110) for LCA10 The first patient was dosed in the Phase …
